These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


157 related items for PubMed ID: 8831761

  • 1. Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.
    Delorme D, Ducharme Y, Brideau C, Chan CC, Chauret N, Desmarais S, Dubé D, Falgueyret JP, Fortin R, Guay J, Hamel P, Jones TR, Lépine C, Li C, McAuliffe M, McFarlane CS, Nicoll-Griffith DA, Riendeau D, Yergey JA, Girard Y.
    J Med Chem; 1996 Sep 27; 39(20):3951-70. PubMed ID: 8831761
    [Abstract] [Full Text] [Related]

  • 2. Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.
    Hamel P, Riendeau D, Brideau C, Chan CC, Desmarais S, Delorme D, Dubé D, Ducharme Y, Ethier D, Grimm E, Falgueyret JP, Guay J, Jones TR, Kwong E, McAuliffe M, McFarlane CS, Piechuta H, Roumi M, Tagari P, Young RN, Girard Y.
    J Med Chem; 1997 Aug 29; 40(18):2866-75. PubMed ID: 9288168
    [Abstract] [Full Text] [Related]

  • 3. Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids.
    Ducharme Y, Brideau C, Dubé D, Chan CC, Falgueyret JP, Gillard JW, Guay J, Hutchinson JH, McFarlane CS, Riendeau D.
    J Med Chem; 1994 Feb 18; 37(4):512-8. PubMed ID: 8120869
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.
    Lau CK, Bélanger PC, Dufresne C, Scheigetz J, Therien M, Fitzsimmons B, Young RN, Ford-Hutchinson AW, Riendeau D, Denis D.
    J Med Chem; 1992 Apr 03; 35(7):1299-318. PubMed ID: 1313879
    [Abstract] [Full Text] [Related]

  • 6. 5-Lipoxygenase inhibitors: synthesis and structure-activity relationships of a series of 1-aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones.
    Bhatia PA, Brooks CD, Basha A, Ratajczyk JD, Gunn BP, Bouska JB, Lanni C, Young PR, Bell RL, Carter GW.
    J Med Chem; 1996 Sep 27; 39(20):3938-50. PubMed ID: 8831760
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthma.
    Chabot-Fletcher MC, Underwood DC, Breton JJ, Adams JL, Kagey-Sobotka A, Griswold DE, Marshall LA, Sarau HM, Winkler JD, Hay DW.
    J Pharmacol Exp Ther; 1995 Jun 27; 273(3):1147-55. PubMed ID: 7791085
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor.
    Shirumalla RK, Sharma P, Dastidar SG, Paliwal JK, Kakar S, Varshney B, Singh Saini G, Sattigeri V, Salman M, Ray A.
    Inflamm Res; 2008 Mar 27; 57(3):135-43. PubMed ID: 18369577
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC.
    Br J Pharmacol; 1997 May 27; 121(1):105-17. PubMed ID: 9146894
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues.
    Zheng M, Zhang Z, Zhu W, Liu H, Luo X, Chen K, Jiang H.
    Bioorg Med Chem; 2006 May 15; 14(10):3428-37. PubMed ID: 16458008
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.
    Grimes D, Sturm RJ, Marinari LR, Carlson RP, Berkenkopf JW, Musser JH, Kreft AF, Weichman BM.
    Eur J Pharmacol; 1993 May 19; 236(2):217-28. PubMed ID: 8391458
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.